Jefferies Financial Group Inc. Grows Stock Holdings in Insulet Corporation $PODD

Jefferies Financial Group Inc. raised its position in shares of Insulet Corporation (NASDAQ:PODD) by 132.0% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 13,361 shares of the medical instruments supplier’s stock after buying an additional 7,602 shares during the period. Jefferies Financial Group Inc.’s holdings in Insulet were worth $3,798,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Winnow Wealth LLC acquired a new position in shares of Insulet during the third quarter valued at about $862,000. Nordea Investment Management AB increased its holdings in shares of Insulet by 35.0% during the fourth quarter. Nordea Investment Management AB now owns 551,133 shares of the medical instruments supplier’s stock valued at $157,128,000 after acquiring an additional 142,922 shares in the last quarter. ING Groep NV increased its holdings in shares of Insulet by 88.5% during the third quarter. ING Groep NV now owns 17,300 shares of the medical instruments supplier’s stock valued at $5,341,000 after acquiring an additional 8,123 shares in the last quarter. Jain Global LLC increased its holdings in shares of Insulet by 148.2% during the third quarter. Jain Global LLC now owns 106,710 shares of the medical instruments supplier’s stock valued at $32,945,000 after acquiring an additional 63,719 shares in the last quarter. Finally, Machina Capital S.A.S. acquired a new position in shares of Insulet during the third quarter valued at about $2,778,000.

Insulet Price Performance

Shares of NASDAQ:PODD opened at $153.80 on Wednesday. Insulet Corporation has a twelve month low of $145.59 and a twelve month high of $354.88. The company’s 50 day moving average is $188.59 and its 200 day moving average is $248.51. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71. The company has a market cap of $10.65 billion, a PE ratio of 35.77, a price-to-earnings-growth ratio of 1.23 and a beta of 1.20.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping the consensus estimate of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The company had revenue of $761.70 million for the quarter, compared to the consensus estimate of $729.89 million. During the same quarter in the prior year, the company earned $1.02 EPS. Insulet’s quarterly revenue was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, sell-side analysts forecast that Insulet Corporation will post 6.43 EPS for the current year.

Analysts Set New Price Targets

PODD has been the topic of several recent analyst reports. Jefferies Financial Group cut their price objective on shares of Insulet from $400.00 to $360.00 in a report on Thursday, May 7th. Truist Financial dropped their price target on Insulet from $315.00 to $250.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. JPMorgan Chase & Co. decreased their target price on Insulet from $340.00 to $275.00 and set an “overweight” rating for the company in a report on Thursday, May 7th. Stifel Nicolaus decreased their target price on Insulet from $350.00 to $250.00 in a report on Thursday, May 7th. Finally, Weiss Ratings downgraded shares of Insulet from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, May 15th. Twenty-one research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $253.87.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.